Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Finished Goods data on file, last reported at $22.0 million in Q1 2026.

• On a quarterly basis, Finished Goods fell 4.84% year-over-year to $22.0 million in Q1 2026; TTM through Mar 2026 was $22.0 million, a 4.84% decrease from a year earlier, with the FY2025 full-year figure at $25.0 million, up 8.7% from the prior year.
• Finished Goods for Q1 2026 stood at $22.0 million, down from $25.0 million in the prior quarter.
• Over the last five years, Finished Goods for RARE reached as high as $26.7 million in Q2 2025 and fell as low as $4.9 million in Q2 2022.
• Historically, Finished Goods has averaged $15.8 million across 5 years, with a median of $14.9 million in 2024.
• Across the five-year window, Finished Goods declined 13.08% in 2022 and soared 107.99% in 2023, its largest moves.
• Year by year, Finished Goods stood at $9.3 million in 2022, then surged by 62.82% to $15.1 million in 2023, then surged by 52.22% to $23.0 million in 2024, then rose by 8.7% to $25.0 million in 2025, then decreased by 12.0% to $22.0 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $22.0 million in Q1 2026, $25.0 million in Q4 2025, and $23.0 million in Q3 2025.